Dr. Lee Marshall has extensive experience in next-generation sequencing and bioinformatics, particularly as it relates to the study of Parkinson’s disease. He earned a B.S. in medical science with honors from University of Western Sydney followed by a Ph.D. from the Garvan Institute of Medical Research, where his main focus was to elucidate the role of long non-coding RNAs in Parkinson’s disease using both global and capture based sequencing approaches. Lee also has extensive experience in both wet lab and bioinformatics. In April 2017, he joined the laboratory of Viviane Labrie, Ph.D., in Van Andel Institute’s Center for Neurodegenerative Science.
Dr. Marshall uses both bioinformatics and wet lab approaches to identify epigenetic and transcriptional changes in Parkinson’s disease and to investigate how these dysregulations may contribute to disease progression. This multiomic approach, backed up by molecular data, will allow for greater insights into how genome, epigenome and transcriptome associate in the progression of Parkinson’s.
Ph.D., Garvan Institute of Medical Research (Advisor: Prof. Anthony Cooper)
Thesis: The role of long non-coding RNAs in Parkinson’s disease
B.S. in medical science, University of Western Sydney
Castle Harlem Research Award (2014)
Research Excellence Award (2013)
Australian Post Graduate Award (2012)
Li P, Marshall L, Oh G, Jakubowski JL, Groot D, He Y, Wang T, Petronis A, Labrie V. 2019. Epigenetic dysregulation of enhancers in neurons is associated with Alzheimer’s disease pathology and cognitive decline. Nat Comm.
Pai S, Li P, Killinger B, Marshall L, Jia P, Liao J, Petronis A, Szabó P, Labrie V. 2019. Differential methylation of enhancer at IGF2 is associated with abnormal dopamine synthesis in major psychosis. Nat Comm.
Chen X, Kordich JK, Williams ET, Levine N, Cole-Strauss A, Marshall L, Labrie V, Ma J, Lipton JW, Moore DJ. 2019. Parkinson’s disease-linked D620N VPS35 knockin mice manifest tau neuropathology and dopaminergic neurodegeneration. Proc Natl Acad Sci U S A.